Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction

S Straw, M McGinlay, KK Witte - Open Heart, 2021 - openheart.bmj.com
HOW DID WE GET HERE? Heart failure guidelines are based around inhibition of the renin-
angiotensin and sympathetic nervous systems, two fundamental pathways which drive the …

Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure

DJ Doherty, KF Docherty, RS Gardner - Heart, 2024 - heart.bmj.com
Guidelines are more accessible than ever and represent an important tool in clinical
practice. The National Institute for Health and Care Excellence (NICE) has developed …

Pharmacotherapy sequencing strategies for patients with heart failure with reduced ejection fraction: a cost–utility analysis

MT Van, P Loewen, M Sadatsafavi, W Zhang… - CMAJ, 2024 - cmaj.ca
Background Standard pharmacotherapy for patients with heart failure with reduced ejection
fraction (HFrEF) comprises “quadruple therapy” with a renin–angiotensin system inhibitor, a …

Disproportionate secondary mitral regurgitation: myths, misconceptions and clinical implications

PA Grayburn, M Packer, A Sannino, GW Stone - Heart, 2021 - heart.bmj.com
Secondary (functional) mitral regurgitation (SMR) most commonly arises secondary to left
ventricular (LV) dilation/dysfunction. The concept of disproportionately severe SMR was …

Temporal trends in heart failure medication prescription in a population-based cohort study

A Uijl, I Vaartjes, S Denaxas, H Hemingway, A Shah… - BMJ open, 2021 - bmjopen.bmj.com
Objective We examined temporal heart failure (HF) prescription patterns in a large
representative sample of real-world patients in the UK, using electronic health records …

Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status …

Y Shiraishi, N Ikemura, M Urashima, T Kohno… - BMJ open, 2024 - bmjopen.bmj.com
Introduction The current guidelines strongly recommend early initiation of multiple classes of
cardioprotective drugs for patients with heart failure with reduced ejection fraction to improve …

impHFrEF trial: study protocol for an open-label, multicentre study of improvement the outcome of patients with heart failure in China using a mobile hEalth-supported …

F Chen, G Li, X Zhang, Q Shen, F Wang, X Dong… - BMJ open, 2024 - bmjopen.bmj.com
Background Patients with chronic heart failure (CHF) often have a long duration of illness,
difficulty in attending follow-up visits, and poor adherence to treatment. As a result, they …

Sequencing of medical therapy in heart failure with a reduced ejection fraction

HO Savage, AD Dimarco, B Li, S Langley… - Heart, 2023 - heart.bmj.com
The management of heart failure with a reduced ejection fraction is a true success story of
modern medicine. Evidence from randomised clinical trials provides the basis for an …

PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study

FDR Hobbs, RI Hussain, C Vitale, YM Pinto… - Open …, 2021 - openheart.bmj.com
Objective To assess current management practice of heart failure with reduced ejection
fraction (HFrEF) in multinational primary care (PC) and determine whether N-terminal-pro-B …

Beta-Blocker Usage in Patients With Heart Failure With Reduced Ejection Fraction During Acute Decompensated Heart Failure Hospitalizations

MT Brennan, KM Harmouch, J Basit… - Ochsner Journal, 2024 - ochsnerjournal.org
Background: Acute decompensated heart failure accounts for more than 1 million
hospitalizations in the United States every year. Beta-blockers are a first-line agent for …